Browse studies

Find your next paid study

3,080 recruiting studies matching your filters

A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung ca…

Advanced Lung AdenocarcinomaRefractory Lung AdenocarcinomaStage III Lung Cancer AJCC v8+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Emory UniversityNCT06495125

Phase 2

A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such …

Hidradenitis SuppurativaAtopic Dermatitis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT06524635

Phase 1

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imnesk…

Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Aulos Bioscience, Inc.NCT05267626

Phase 3

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)

This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with…

ENSAT Stage I Adrenal Cortex CarcinomaENSAT Stage II Adrenal Cortex CarcinomaENSAT Stage III Adrenal Cortex Carcinoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT03583710

Phase 1

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or re…

Advanced Solid TumorsMetastatic Pancreatic CancerPediatric Solid Tumor+3 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04222413

Observational

Preoperative Virtual Reality and 3D Pathologic Modeling as Treatment for Head and Neck Squamous Cell Carcinoma

This clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and…

Head and Neck Squamous Cell Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT05031910

Phase 1

A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-…

B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Marlise Luskin, MDNCT03595917

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP),…

Chronic Inflammatory Demyelinating PolyradiculoneuropathyCIDPCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Estimated

Pay not disclosed — ask the coordinator

argenxNCT07264426

Observational

Trial Time for Percutaneous Nerve Evaluation in Patients Undergoing Sacral Neuromodulation for Urgency Urinary Incontinence or Urgency-frequency: a Randomized Control Trial

Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial p…

Urge IncontinenceUrgency-frequency SyndromeOveractive Bladder

Estimated

~$10 – $750

Actual pay is set by the research site.

University of ChicagoNCT06226220

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for w…

Lower Urinary Tract SymptomsStress Urinary IncontinenceUrge Urinary Incontinence+6 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Hartford HealthCareNCT07175805

Phase 1

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination With Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.

Glioblastoma MultiformeAstrocytoma, Grade III

Estimated

~$150 – $4,500

Actual pay is set by the research site.

David Baskin MDNCT03596086

Phase 1

A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, to…

Advanced CancerAdvanced Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Shanghai Allink Biotherapeutics Co., Ltd.NCT06707610